
Accomplished leader in Hemostasis and Thrombosis Center operations, delivering multidisciplinary care for bleeding and clotting disorders. Directs nursing operations, quality improvement, and regulatory compliance while enhancing care coordination and patient education. Manages the 340B Drug Pricing Program, ensuring compliance and optimizing resources to increase patient access. Drives quality initiatives and process improvements, focusing on patient safety and strategic growth.
Methodical director with several years of comprehensive experience overseeing daily operations of program. Hardworking and versatile professional well-versed in executing new policies, preparing and implementing business plans and overseeing financial performance.
3901 Beaubien Blvd, Detroit, MI, 48201
A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease, Hyde, M., Sabo, C., Stadler, C., Rapurkar, M., 05/26, Journal of Thrombosis and Haemostasis, https://doi.org/10.1016/j.jtha.2025.12.029